VYNE Therapeutics (VYNE) Enterprise Value (2016 - 2025)
VYNE Therapeutics (VYNE) has disclosed Enterprise Value for 10 consecutive years, with -$29.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 52.84% year-over-year to -$29.0 million, compared with a TTM value of -$29.0 million through Dec 2025, up 52.84%, and an annual FY2025 reading of -$29.0 million, up 52.84% over the prior year.
- Enterprise Value was -$29.0 million for Q4 2025 at VYNE Therapeutics, down from -$17.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$15.4 million in Q3 2023 and bottomed at -$119.5 million in Q1 2021.
- Average Enterprise Value over 5 years is -$51.8 million, with a median of -$42.8 million recorded in 2022.
- The sharpest move saw Enterprise Value crashed 278.51% in 2024, then soared 77.47% in 2025.
- Year by year, Enterprise Value stood at -$42.2 million in 2021, then increased by 27.34% to -$30.7 million in 2022, then tumbled by 203.79% to -$93.3 million in 2023, then skyrocketed by 34.03% to -$61.5 million in 2024, then skyrocketed by 52.84% to -$29.0 million in 2025.
- Business Quant data shows Enterprise Value for VYNE at -$29.0 million in Q4 2025, -$17.6 million in Q2 2025, and -$22.1 million in Q1 2025.